Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) generates a steady stream of news related to pharmaceutical development, drug delivery technology and commercial progress. Company announcements emphasize its proprietary AmorphOX powder-based platform, clinical studies of intranasal rescue medications, and collaborations that extend its technology to new therapeutic areas.
Readers of this news feed can follow updates on Orexo’s work in opioid use disorder treatments in the U.S. market, as well as development projects such as OX124, a high-dose naloxone rescue medication for opioid overdose. Interim reports provide context on revenues, cash flow, and the performance of the U.S. Commercial segment, alongside commentary from management on business development and regulatory interactions.
A significant portion of Orexo’s recent news focuses on the AmorphOX platform and its application to intranasal formulations. This includes clinical and preclinical results for OX640, a nasal epinephrine powder product for severe allergic reactions including anaphylaxis, and preclinical data on powder-based intranasal semaglutide formulations. Company releases describe pharmacokinetic and pharmacodynamic findings, such as absorption profiles, plasma levels and effects on blood pressure and heart rate.
Another recurring news theme is collaboration on nasal powder vaccines. Orexo reports on its partnership with Abera Bioscience to combine AmorphOX with a vaccine platform for mucosal vaccines, including intranasal influenza vaccine candidates. Updates cover proof-of-concept immune response data and the potential implications for vaccine stability and administration.
Investors and observers can also track corporate governance items, such as the composition of the nomination committee for the annual general meeting, and participation in healthcare conferences. Bookmarking this page allows users to monitor Orexo’s clinical milestones, technology developments and financial disclosures as they are released.
Orexo has announced a partnership with GoGoMeds to provide digital therapies, deprexis® for depression and vorvida® for alcohol misuse, making them available to those in need. Additionally, OXD01, aimed at treating opioid use disorder, will launch in the U.S. by Q4 2020. The COVID-19 pandemic has increased demand for such digital solutions. The therapies are designed to improve access to mental health care, utilizing AI for tailored content, and are accessible anytime, anywhere. This collaboration seeks to support various addiction services across the U.S.